Skip to main content


Lead: Cormac Flynn

RegenoMac is a novel solution to treat blindness dur to diabetes which is the leading cause of blindness in the developed world. Current therapies lack efficacy but RegenoMac unique mechanism of action directly targets the vision threatening part of the disease and restores vision beyond where standard of care alone can acheive. Global sales in 2021 for the market leader therapy Eylea was $9.8Bn and patients and clinicians are eager for new therapies that are more effective. We have shown safety of our new therapy using a challenging 7 day healthy rabbit study and aim to demonstrate efficacy in a longer study starting in 2022. We have runway to October 2023 and are currently raising our seed round of investment for €750,000.